← Back to Clinical Trials
Recruiting NCT06048419

NCT06048419 Acceptability and Efficacy of GO MOVE

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06048419
Status Recruiting
Phase
Sponsor Texas Scottish Rite Hospital for Children
Condition Cerebral Palsy
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-02-20
Primary Completion 2026-09

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 17 Years
Study Type INTERVENTIONAL
Interventions
Home Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2024-02-20 with a primary completion date of 2026-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to learn about the acceptability and efficacy of Go Move, a mobile website developed to assist youth with unilateral cerebral palsy and their caregivers with setting goals and selecting exercises and activities to meet the goals. The main question\[s\] it aims to answer are: * Is Go Move accepted by youth with unilateral cerebral palsy and their caregivers? * Does Go Move support goal attainment for youth with unilateral cerebral palsy? Participants will set up and participate in a goal-driven home program using the Go Move mobile website. Participants will spend 1 hour and 15 minutes per week for 6 weeks working on their home program and will complete pre-intervention and post-intervention assessments.

Eligibility Criteria

Inclusion Criteria: * Inclusion criteria for participants to enroll in the study include a diagnosis of unilateral CP or a non-progressive brain lesion, injury, or trauma of the developing brain that presents with a unilateral upper limb motor impairment. GMFCS levels 1 or 2. MACS levels 1-3. Age 3-17 years old, ability to follow directions, ability to complete the assessment protocol, and the ability to access the GO MOVE webpage on a personal device. All ethnic/racial groups will be eligible to participate. The ability to participate in everyday activities without restriction from a physician throughout the duration of their participation in the study (does not have restrictions/contraindications following a medical procedure). Exclusion Criteria: * The study will exclude any patients with uncontrolled epilepsy or significant visual impairment. The study will exclude any patient with severe behavioral problems or the inability to complete the assessment protocol or home program.

Contact & Investigator

Central Contact

Angela Shierk, PhD

✉ angela.shierk@tsrh.org

📞 4694127172

Principal Investigator

Angela Shierk, PhD

PRINCIPAL INVESTIGATOR

Scottish Rite for Children

Frequently Asked Questions

Who can join the NCT06048419 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 17 Years, studying Cerebral Palsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06048419 currently recruiting?

Yes, NCT06048419 is actively recruiting participants. Contact the research team at angela.shierk@tsrh.org for enrollment information.

Where is the NCT06048419 trial being conducted?

This trial is being conducted at Frisco, United States.

Who is sponsoring the NCT06048419 clinical trial?

NCT06048419 is sponsored by Texas Scottish Rite Hospital for Children. The principal investigator is Angela Shierk, PhD at Scottish Rite for Children. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology